Huperzine A in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis
Xing SH, Zhu CX, Zhang R, An L
Published in Evidence-Based Complementary and Alternative Medicine
Methodology
Meta-analysis of randomised controlled trials of huperzine A in Alzheimer's disease and vascular dementia
Key Findings
Huperzine A significantly improved MMSE and ADL scores in both Alzheimer's disease and vascular dementia with a low rate of mild cholinergic adverse events.
Conclusions
Huperzine A shows consistent but low-certainty cognitive benefit in dementia populations.
Limitations
Included trials small and mostly unblinded to allocation concealment standards.
Supplements Studied
Huperzine A significantly improved MMSE and ADL scores in both Alzheimer's disease and vascular dementia.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.